换一批Lkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy.
第一作者：
Cristina M,Contreras
第一单位：
Department of Pathology, UT Southwestern Medical Center, UT Southwestern Medical Center, Dallas, TX 75390, USA.
作者：
医学主题词
AMP活化蛋白激酶类(AMP-Activated Protein Kinases);动物(Animals);细胞系, 肿瘤(Cell Line, Tumor);克隆, 分子(Cloning, Molecular);角化包膜富含脯氨酸蛋白质类(Cornified Envelope Proline-Rich Proteins);疾病模型, 动物(Disease Models, Animal);药物筛选试验, 抗肿瘤(Drug Screening Assays, Antitumor);子宫内膜肿瘤(Endometrial Neoplasms);子宫内膜(Endometrium);酶激活(Enzyme Activation);上皮(Epithelium);女(雌)性(Female);整合酶类(Integrases);细胞内信号肽和蛋白质类(Intracellular Signaling Peptides and Proteins);小鼠(Mice);小鼠, 转基因(Mice, Transgenic);肿瘤侵润(Neoplasm Invasiveness);器官特异性(Organ Specificity);外显率(Penetrance);蛋白激酶抑制剂(Protein Kinase Inhibitors);反应元件(Response Elements);西罗莫司(Sirolimus);TOR丝氨酸-苏氨酸激酶(TOR Serine-Threonine Kinases)
DOI
10.1242/dmm.004440
PMID
20142330
发布时间
2021-12-03
- 浏览2
Disease models & mechanisms
181-93页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
